Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | NTRK2 over exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Trk Receptor Inhibitor (Pan) |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| NTRK2 over exp | neuroblastoma | sensitive | Trk Receptor Inhibitor (Pan) | AZ64 + Irinotecan + Temozolomide | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AZ64 in combination with Camptosar (irinotecan) and Temodar (temozolomide) improved event-free survival and reduced tumor growth in neuroblastoma cell line xenograft models over expressing Ntrk2 (TrkB), with increased efficacy over chemotherapy alone (PMID: 22623209). | 22623209 |
| NTRK2 over exp | neuroblastoma | sensitive | Trk Receptor Inhibitor (Pan) | AZ64 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AZ64 inhibited tumor growth in neuroblastoma cell line xenograft models over expressing Ntrk2 (TrkB) (PMID: 22623209). | 22623209 |